Literature DB >> 34518964

Comparison of the Euroimmun Borrelia 'antibody index' with Virotech immunoblot-based detection of intrathecal Borrelia antibody production for the diagnosis of Lyme neuroborreliosis.

Erika De Bont1, Katrien Lagrou2,3, Melissa Depypere2,3.   

Abstract

For diagnosis of neuroborreliosis, calculation of the antibody index, based on Euroimmun Anti-Borrelia plus VlsE ELISA was compared to Virotech Borrelia Europe plus TpN17 immunoblot-based detection of Borrelia-specific intrathecal antibody production. CXCL13 results in cerebrospinal fluid were used to evaluate discordant results. A total of 64 serum/CSF pairs were analysed. Patients were classified according to European Federation of Neurological Societies criteria incorporating Virotech results. For the Euroimmun assay, a sensitivity of 100% and specificity of 94% was found. Agreement between the both tests was almost perfect (κ 0.81). Both methods are appropriate for the detection of Borrelia-specific intrathecal antibody production.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Antibody index; CXCL13; Euroimmun; Immunoblot; Neuroborreliosis; Virotech

Mesh:

Substances:

Year:  2021        PMID: 34518964     DOI: 10.1007/s10096-021-04343-x

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  17 in total

1.  Clinical comparison of immunoblot and antibody index for detection of intrathecal synthesis of specific antibodies in Lyme neuroborreliosis.

Authors:  D Pícha; L Moravcová; E Zdárský; J Benes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-10       Impact factor: 3.267

2.  Intrathecally produced IgG and IgM antibodies to recombinant VlsE, VlsE peptide, recombinant OspC and whole cell extracts in the diagnosis of Lyme neuroborreliosis.

Authors:  Gerold Stanek; Lara Lusa; Katarina Ogrinc; Mateusz Markowicz; Franc Strle
Journal:  Med Microbiol Immunol       Date:  2013-12-23       Impact factor: 3.402

3.  Different B-cell populations are responsible for the peripheral and intrathecal antibody production in neuroborreliosis.

Authors:  András Lakos; Emoke Ferenczi; Sámuel Komoly; Marta Granström
Journal:  Int Immunol       Date:  2005-11-22       Impact factor: 4.823

4.  Relative frequency of Lyme borreliosis and of its clinical manifestations in Europe. European Community Concerted Action on Risk Assessment in Lyme Borreliosis.

Authors:  M A Cimmino
Journal:  Infection       Date:  1998 Sep-Oct       Impact factor: 3.553

Review 5.  Lyme borreliosis in Europe and North America.

Authors:  J Piesman; L Gern
Journal:  Parasitology       Date:  2004       Impact factor: 3.234

Review 6.  Lyme borreliosis.

Authors:  R B Nadelman; G P Wormser
Journal:  Lancet       Date:  1998-08-15       Impact factor: 79.321

7.  EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis.

Authors:  A Mygland; U Ljøstad; V Fingerle; T Rupprecht; E Schmutzhard; I Steiner
Journal:  Eur J Neurol       Date:  2009-11-23       Impact factor: 6.089

8.  Laboratory diagnosis of Lyme neuroborreliosis is influenced by the test used: comparison of two ELISAs, immunoblot and CXCL13 testing.

Authors:  Nora Wutte; Juan Archelos; Brian A Crowe; Werner Zenz; Elisabeth Daghofer; Franz Fazekas; Elisabeth Aberer
Journal:  J Neurol Sci       Date:  2014-09-26       Impact factor: 3.181

9.  The recomBead Borrelia antibody index, CXCL13 and total IgM index for laboratory diagnosis of Lyme neuroborreliosis in children.

Authors:  B H Skogman; M Lager; A J Henningsson; I Tjernberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-07-20       Impact factor: 3.267

10.  Laboratory diagnosis of Lyme neuroborreliosis: a comparison of three CSF anti-Borrelia antibody assays.

Authors:  A J Henningsson; M Christiansson; I Tjernberg; S Löfgren; A Matussek
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-11-22       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.